Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF10 plus Ipilimumab in Advanced Melanoma
NCT02272855Phase 2Completed
- Sponsor
- Takara Bio Inc.
- Start
- Apr 2014
- Primary completion
- Oct 2016
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of canerpaturev in Malignant Melanoma (MM), sponsored by Takara Bio Inc.. Started Apr 2014; status: completed.
02
Drugs
canerpaturev
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02272855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272855.